Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101
Toolkit: New Legislative and Medicaid Models to Lower Drug Prices
/in Policy, Prescription Drug Pricing Featured News Home, Toolkits Prescription Drug Pricing /by NASHP StaffNew NASHP Model Legislation Supports State Efforts to Lower Drug Costs by Leveraging Medicare Negotiations
/in Model Legislation and Contracts, Policy, Prescription Drug Pricing Blogs, Featured News Home Model Legislation, Prescription Drug Pricing /by Drew Gattine and Jennifer ReckNASHP Releases Model State Legislation to Lower the Cost of Prescription Drugs
/in Model Legislation and Contracts, Policy, Prescription Drug Pricing Blogs, Featured News Home Model Legislation /by Drew Gattine and Kris VallecilloState Drug Pricing Laws: 2017-2022
/in Prescription Drug Pricing Newly-Enacted Laws, Prescription Drug Pricing /by NASHP Staff2022 State Legislative Action to Lower Pharmaceutical Costs
/in Prescription Drug Pricing Featured News Home, Maps Cost, Payment, and Delivery Reform, Health System Costs, Legislative Tracker, Prescription Drug Pricing, State Rx Legislative Action Prescription Drug Pricing /by NASHP StaffThe Inflation Reduction Act’s Health Care Provisions: Opportunities for States
/in Prescription Drug Pricing Blogs, Featured News Home Newly-Enacted Laws, State Insurance Marketplaces /by Jennifer Reck and Christina CousartFDA User Fee Reauthorization Package May Impact State Importation Programs
/in Policy, Prescription Drug Pricing Blogs, Featured News Home Prescription Drug Pricing /by Johanna ButlerNASHP Announces RFP to Support PDAB States — Due July 26, 2022
/in Prescription Drug Pricing Featured News Home Prescription Drug Pricing /by Jennifer ReckState Drug Price Transparency Programs Identify Critical Data on High Cost Drugs
/in Policy, Prescription Drug Pricing Maine, Oregon, Washington Blogs, Featured News Home Prescription Drug Pricing /by Johanna Butler and Jennifer ReckStates’ drug price transparency programs are effectively analyzing and reporting data — an important tool for informing the public, holding drug supply chain entities accountable for high costs, and identifying potential policy approaches. Leading states are highlighting high prices for anti-inflammatory drugs, the impact of pharmacy benefit manager (PBM) regulation on drug spending and the […]
Washington Joins Leading States in Establishing a Prescription Drug Affordability Board
/in Policy, Prescription Drug Pricing Washington Featured News Home Newly-Enacted Laws, Prescription Drug Pricing /by Jennifer ReckOn March 24, 2022, Washington state joined five other leading states in establishing a Prescription Drug Affordability Board (PDAB) when Governor Inslee signed SB 5532, sponsored by Senator Karen Keiser, into law. Washington’s PDAB, like those already established in Maryland and Colorado, has the authority to limit what payers in the state will pay for […]